



28 July 2016

ASX ANNOUNCEMENT

APPENDIX 4C – Quarter Ended 30 June 2016

Brisbane, Australia - ImpediMed Limited (ASX: IPD) a global provider of medical technology to measure, monitor and manage fluid status and body composition, today released its Appendix 4C – Quarterly cash flow report for the period ended 30 June 2016.

Total revenue for the period was \$1.6 million, including lymphoedema sales of \$1.0 million. Net operating cash outflow for the quarter was \$6.8 million. Cash receipts from customers for the quarter were \$1.5 million and cash on hand as of June 30 2016 was \$82.3 million.

Highlights for the past quarter include:

- Entered into a multi-location five-year master clinical trial agreement with the Mayo Clinic to explore additional indications for ImpediMed's fluid status and body composition technology. The agreement covers clinical trials to be conducted using ImpediMed's BIS technology devices for future indications;
- Trained 16 new L-Dex accounts in Q2, have now signed and trained 33 of 50 targeted L-Dex accounts for CY2016 in the first half since commercial launch; integration into electronic health records have been completed in a number of these accounts;
- Continued to accelerate the development of next generation device for both clinical and at-home settings;
- Progressed the development of our CHF clinical program;
- Established a regional office in Minnesota to expand our operations, marketing, product and business development functions.

“We continued to make great progress in the quarter with signing and training our targeted L-Dex accounts for our oncology roll-out, our next generation product development, and constructing and advancing the CHF clinical program. The 5-year, multi-location clinical trial master agreement entered into with the Mayo Clinic was also very important for us, and will enable us to further expedite the future investigation of many new applications for our technology as we move forward,” said Richard Carreon, Managing Director and CEO of ImpediMed.

Investor Conference Call – Tuesday 2 August 2016 11:00AM AEST (GMT +10)

ImpediMed invites investors to join a conference call hosted by Managing Director and CEO Richard Carreon and CFO Morten Vigeland on Tuesday 2 August 2016 at 11:00am AEST.

To access the call please use the dial in details below:

For personal use only

Australia Toll Free: 1 800 558 698
Alt Australia Toll Free: 1 800 809 971
Australia Local: 02 9007 3187
New Zealand Toll Free: 0800 453 055
NZ Local (Auckland): 09 929 1687
NZ Local (Wellington): 04 974 7738
NZ Local (Christchurch): 03 974 2632
China Wide: 4001 200 659
Belgium: 0800 72 111
Canada: 1855 8811 339
France: 0800 913 848
Germany: 0800 182 7617
Hong Kong: 800 966 806
India: 0008 0010 08443
Indonesia: 001 803 019 3275
Ireland: 1800 948 625
Italy: 800 793 500
Japan: 0053 116 1281

Malaysia: 1800 816 294
Netherlands: 0800 020 0715
Norway: 800 69 950
Philippines: 1800 1110 1462
Singapore: 800 101 2785
South Korea: 00 798 142 063 275
Sweden: 020 791 959
South Africa: 0800 999 976
Switzerland: 0800 820 030
Taiwan: 008 0112 7397
Thailand: 001800 156 206 3275
UAE: 8000 3570 2705
United Kingdom: 0800 051 8245
United States: (855) 881 1339
US Local (New York): (914) 202 3258
US Local (Los Angeles): (909) 235 4020
US Local (Chicago): (815) 373 2080

Conference Call ID: 947381

Richard Carreon
Managing Director & CEO

For further information, contact:

Richard Carreon, ImpediMed Managing Director & CEO
Morten Vigeland, ImpediMed CFO
T: +1 (760) 585-2100

Media Contacts:

In Australia:

Kyahn Williamson, Buchan
T: +61 3 9866 4722
E: kwilliamson@buchanwe.com.au

In the US:

Paul Maccabee/Andy Pollen, Maccabee PR
T: +1 612-337-0087
E: paul@maccabee.com; andy@maccabee.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., ImpediMed is the world leader in the development and distribution of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status in patients. ImpediMed has the first medical device with FDA clearance in the U.S. to aid healthcare professionals to clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men. For additional information, visit www.impedimed.com.

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

ImpediMed Limited

ABN

65 089 705 144

Quarter ended ("current quarter")

30 June 2016

Consolidated statement of cash flows

Cash flows related to operating activities		Current quarter	Year to date (twelve months)
		\$A'000	\$A'000
1.1	Receipts from customers	1,514	5,686
1.2	Payments for		
	(a) staff costs	(3,432)	(13,436)
	(b) advertising and marketing	(486)	(1,136)
	(c) research and development	(1,869)	(4,010)
	(d) leased assets	(4)	(22)
	(e) other working capital	(2,610)	(9,616)
1.3	Dividends received	0	0
1.4	Interest and other items of a similar nature received	74	112
1.5	Interest and other costs of finance paid	0	0
1.6	Income taxes paid	0	0
1.7	Other (provide details if material)	0	0
	Net operating cash flows	(6,813)	(22,422)

+ See chapter 19 for defined terms.

For personal use only

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter	Year to date (twelve months)
	\$A'000	\$A'000
1.8 Net operating cash flows (carried forward)	(6,813)	(22,422)
1.9 Cash flows related to investing activities		
Payment for acquisition of:		
(a) businesses (item 5)	0	0
(b) equity investments	0	0
(c) intellectual property	0	0
(d) physical non-current assets	(55)	(109)
(e) other non-current assets	0	0
1.10 Proceeds from disposal of:		
(a) businesses (item 5)	0	0
(b) equity investments	0	0
(c) intellectual property	0	0
(d) physical non-current assets	0	0
(e) other non-current assets	0	0
1.11 Loans to other entities	0	0
1.12 Loans repaid by other entities	0	0
1.13 Other (provide details if material)	0	0
Net investing cash flows	(55)	(109)
1.14 Total operating and investing cash flows	(6,868)	(22,531)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.	53	71,458
1.16 Release of restricted cash	0	0
1.17 Proceeds from borrowings	0	0
1.18 Repayment of borrowings	0	0
1.19 Dividends paid	0	0
1.20 Other (provide details if material)	0	0
Net financing cash flows	53	71,458
Net increase (decrease) in cash held	(6,815)	48,927
1.21 Cash at beginning of quarter/year to date	86,106	32,582
1.22 Exchange rate adjustments to item 1.20	2,963	745
1.23 Cash at end of quarter	82,254	82,254

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	169
1.25	Aggregate amount of loans to the parties included in item 1.11	0

1.26 Explanation necessary for an understanding of the transactions

Item 1.24: Payments to directors consist of Directors' salaries and superannuation and Directors' fees for the quarter and year-to-date. These figures include only Non-Executive Directors and exclude Directors' salaries and Directors' fees that were accrued and unpaid as at the end of the quarter. At 30 June 2016 there were nil fees accrued and unpaid.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position.

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	---	---
3.2	Credit standby arrangements	---	---

+ See chapter 19 for defined terms.

For personal use only

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.		Current quarter	Previous quarter
		\$A'000	\$A'000
4.1	Cash on hand and at bank	2,586	7,859
4.2	Deposits at call	79,668	78,247
4.3	Bank overdraft	0	0
4.4	Other (provide details)	0	0
Total: cash at end of quarter (item 1.23)		82,254	86,106

Acquisitions and disposals of business entities

		Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1	Name of entity	N/A	N/A
5.2	Place of incorporation or registration	N/A	N/A
5.3	Consideration for acquisition or disposal	N/A	N/A
5.4	Total net assets	N/A	N/A
5.5	Nature of business	N/A	N/A

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:



Date:

28 July 2016

Print name: Morten Vigeland
Chief Financial Officer

+ See chapter 19 for defined terms.

For personal use only

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.

For personal use only